← Browse by Condition
Medical Condition
recurrent small lymphocytic lymphoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT04169737 Phase 2
Recruiting
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment
168 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07061951 Phase 2
Recruiting
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Enrollment
20 pts
Location
United States
Sponsor
National Cancer Institute (NCI...